Boehringer Ingelheim is partnering with Quallent Pharmaceuticals to help expand access to citrate-free adalimumab-adbm, Boehringer’s biosimilar to adalimumab (Humira), in the U.S.
Under the terms of the agreement, Boehringer Ingelheim will manufacture adalimumab-adbm for Quallent. Boehringer Ingelheim will continue to commercialize Boehringer Ingelheim-labeled Cyltezo (adalimumab-adbm) injection and adalimumab-adbm.
Quallent will be offering both high-concentration (40 mg/0.4 mL) and low-concentration (40 mg/0.8 mL) citrate-free formulations of adalimumab-adbm as a pre-filled syringe or pen. Adalimumab-adbm’s interchangeability designation for the low-concentration formulation will extend to Quallent’s 40 mg/0.8 mL private-labeled adalimumab-adbm.
“Our collaboration with Quallent will increase availability of our adalimumab biosimilar for patients living with certain chronic inflammatory diseases,” says Chris Marsh, Senior Vice President of Value and Access at Boehringer Ingelheim, in a news release. “The utilization of biosimilars such as adalimumab-adbm provides the potential for more patients to benefit from biologic medicines and saves costs for both patients and the U.S. healthcare system overall. We’re committed to helping the biosimilar market reach its potential, and this partnership is an important step in enabling greater adoption of these lower-cost options.”
John Caulfield, President of Quallent Pharmaceuticals Health, LLC, adds that Quallent plans to offer a copay assistance program, which will provide eligible patients access.
